SAN DIEGO, Feb. 2, 2016 /PRNewswire/ -- Mast Therapeutics,
Inc. (NYSE MKT: MSTX), a biopharmaceutical company developing novel
clinical-stage therapies for sickle cell disease and heart failure
today announced that the Company's Chief Executive Officer,
Brian M. Culley, will present at the
2016 BIO CEO & Investor Conference on Monday, February 8, 2016 at 2:00 p.m. Eastern time in the Conrad Salon at the
Waldorf Astoria hotel in New
York.
Interested parties can access a live audio webcast on the Mast
Therapeutics web site at www.masttherapeutics.com. An archived
presentation will be available on the web site for 30 days.
About Mast Therapeutics
Mast Therapeutics, Inc. is a
publicly traded biopharmaceutical company headquartered in
San Diego, California. The Company
is leveraging its MAST platform, derived from over two decades of
clinical, nonclinical and manufacturing experience with purified
and non-purified poloxamers, to develop vepoloxamer (also known as
MST-188), its lead product candidate, for serious or
life-threatening diseases and conditions typically characterized by
impaired microvascular blood flow and damaged cell membranes.
The Company is also developing AIR001, a sodium nitrite solution
for inhalation via nebulization.
Vepoloxamer is an investigational new drug being tested in a
pivotal Phase 3 study called EPIC for the treatment of
vaso-occlusive crisis in patients with sickle cell disease and in a
Phase 2 study for the treatment of patients with chronic heart
failure. AIR001 is an investigational new drug in Phase 2a
clinical development for the treatment of patients with heart
failure with preserved ejection fraction (HFpEF). More information
can be found on the Company's web site at www.masttherapeutics.com.
(Twitter: @MastThera)
Mast Therapeutics™ and the corporate logo are trademarks of Mast
Therapeutics, Inc.
Logo -
http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mast-therapeutics-to-present-at-2016-bio-ceo--investor-conference-on-february-8th-300213208.html
SOURCE Mast Therapeutics, Inc.